First slide После первого Second slide Third slide Fourth slide Fifth slide Sixth slide Seventh slide Eighth slide
Home Mission Cooperation with International Organisations News and events About Uzbekistan Photo gallery

WHO recommends two new drugs for COVID-19 treatment

2020 - Year of active investment and social development 2020 - Year of active investment and social development Decrees of the President of the Republic of Uzbekistan Presidential elections of the Republic of Uzbekistan - 2021 Presidential elections of the Republic of Uzbekistan - 2021 Meetings Meetings The international cooperation The international cooperation Millenium development goals Millenium development goals Press-releases Press-releases Mission News Mission News The Strategy of Actions on Further Development The Strategy of Actions on Further Development Independence Day of the Republic of Uzbekistan Independence Day of the Republic of Uzbekistan Uzbekistan's Candidacy to Human Rights Council Uzbekistan’s Candidacy to Human Rights Council Tourism Tourism December 8 - Constitution Day of the Republic of Uzbekistan December 8 - Constitution Day of the Republic of Uzbekistan Press Digests of Uzbekistan Press Digests of Uzbekistan Other news and events Other news and events
show all useful links
WHO recommends two new drugs for COVID-19 treatment

WHO has recommended two new drugs for COVID-19, providing yet more options for treating the disease. The extent to which these medicines will save lives depends on how widely available and affordable they will be.

According to WHO, the first drug, baricitinib, is strongly recommended for patients with severe or critical COVID-19. It is part of a class of drugs called Janus kinase (JAK) inhibitors that suppress the overstimulation of the immune system. WHO recommends that it is given with corticosteroids.

WHO has also conditionally recommended the use of a monoclonal antibody drug, sotrovimab, for treating mild or moderate COVID-19 in patients who are at high risk of hospitalization. This includes patients who are older, immunocompromised, having underlying conditions like diabetes, hypertension, and obesity, and those unvaccinated.

Sotrovimab is an alternative to casirivimab-imdevimab, a monoclonal antibody cocktail recommended by WHO in September 2021. Studies are ongoing on the effectiveness of monoclonal antibodies against Omicron but early laboratory studies show that sotrovimab retains its activity.

The two newly recommended drugs – baricitinib and sotrovimab – have been invited for WHO Prequalification, which assesses the quality, efficacy and safety of priority health products to increase access in lower income countries.

UzA